- Home
- IMC vs SVRA Comparison
IMC vs SVRA Comparison
Compare IMC & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMC | SVRA |
|---|---|---|
| Founded | 2025 | 2007 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2026 | 2009 |
Fundamental Metrics
Financial Performance| Metric | IMC | SVRA |
|---|---|---|
| Price | $7.27 | $4.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.06 |
| AVG Volume (30 Days) | 91.3K | ★ 2.2M |
| Earning Date | 11-03-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4,406.08 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.80 | $3.35 |
| 52 Week High | $11.84 | $7.01 |
Technical Indicators
Market Signals| Indicator | IMC | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 48.58 | 42.19 |
| Support Level | $6.37 | $4.77 |
| Resistance Level | $8.29 | $5.53 |
| Average True Range (ATR) | 1.02 | 0.24 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 14.90 | 30.81 |
Price Performance
Historical ComparisonAbout IMC IMC Rare Earths Ltd Ordinary Shares
IMC Rare Earths Ltd is a mineral exploration and development company engaged in the exploration, evaluation and development of minerals and metals in Brazil. Its main REE project is the Itarantim Project located in the States of Bahia and Minas Gerais, Brazil.
About SVRA Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).